Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 M2rGVWN6fG:2b4jpZ{BCe3OjeR?= MYqxNEBvVQ>? NELTWYQ4OiCq NXHJfW5iTE2VTx?= MlfCVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NX3JTGhpOjR7MEC4O|M>
HT-29 M3HoVWN6fG:2b4jpZ{BCe3OjeR?= NIm2cpYyOCCwTR?= M2fhSVczKGh? MV3EUXNQ M3jCe3BwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= MWCyOFkxODh5Mx?=
HT-29 M{\ZUWN6fG:2b4jpZ{BCe3OjeR?= MmnFNVAhdk1? NInudnA4OiCq NYSwXnZ3TE2VTx?= MnTUVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> NYrqRmh1OjR7MEC4O|M>
PC3 NVTUOHdzU2mwYYPlJGF{e2G7 NGqxNY0yODBibl2= MmX3NUBp M1\GcmROW09? MV7Qc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= MXiyNVk4QDZ6Mx?=
PC3 M4TUN2tqdmG|ZTDBd5NigQ>? NYHNZmJjOTByIH7N NYTLOVZuOSCq MW\EUXNQ MkPVSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MnXlNlE6Pzh4OEO=
PC3 M3\2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxMlUh|ryP NETPVJYyKGh? MVvEUXNQ NGm2[m9KdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= NXTxVGViOjF7N{i2PFM>
HEK293 MYrGeY5kfGmxbjDBd5NigQ>? MY[xNFAhdk1? M1L0PVghcA>? MV3EUXNQ NIDYZ45KdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= NWnwZ4xzOjF3M{mzNFE>
BT-20 MmfxT4lv[XOnIFHzd4F6 NV;wV4xmOjBizszN NGPDT4VFVVOR NGLVSoxFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= NU\ZV4xGOjF|NUO1OVE>
U937 MWfBcpRq[mGldHXybYFtKEG|c3H5 MlXmOVAh|ryP MYK0PEBp M1q2NmROW09? NWrlNnRpUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz NFPvNmgzOTF2MkGwOi=>
U937 NITqdVRCdnSrYnHjeIVzcWGuIFHzd4F6 MorrOVAh|ryP MYm0PEBp MWHEUXNQ MoPESI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBOUVBicILveIVqdi2mZX\pZ4lmdnRiTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBLWjN{LUKgbY4hXTl|NzDj[Yxtew>? M2nR[FIyOTR{MUC2
U937 M33lSWFvfGmkYXP0[ZJq[WxiQYPzZZk> M174UVUxKM7:TR?= M1KxdlQ5KGh? MkToSG1UVw>? NFjXTFNFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? NYn6Zo9bOjFzNEKxNFY>
MCF-7 NI\mepNCfXSxcHjh[5khSXO|YYm= MnvHN|Ahdk1? MlX4OEBp MmrTSG1UVw>? M4DJbWlv\HWlZYOgZZV1d3CqYXf5 MmfYNlAxOjhzM{S=
U87MG MYTLbY5ie2ViQYPzZZk> Mn7MNUDPxE1? Ml60OkBp NEfKendFVVOR MmHzVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? MYCxPVg1QDRyNB?=
U87MG M1iyZ2tqdmG|ZTDBd5NigQ>? MlW2NUDPxE1? NV7R[ZlmPiCq NWLoWZI1TE2VTx?= NHq4S25Rd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=> NV7VT3dwOTl6NEi0NFQ>
U87MG MX7LbY5ie2ViQYPzZZk> NVO2elE{OSEQvF2= NU\xNJZsPiCq MXfEUXNQ NWqycplWTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= MnL3NVk5PDh2MES=
U87MG NXTxNlJVU2mwYYPlJGF{e2G7 Mm\yNUDPxE1? NGP5OpU3KGh? M{noe2ROW09? NFH6OFNFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25? Mn:yNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb MkXyRZV1d3CqYXf5JGF{e2G7 NGfwVXExNjJizszN NWizfJZzOjRiaB?= NFqx[2JFVVOR NYPqN4RlUW6mdXPld{BifXSxcHjh[5k> MmfZNVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 NXTjcmRwSXW2b4DoZYd6KEG|c3H5 MXOwMlIh|ryP MUGyOEBp M4XuPGROW09? NYrv[3dUUW6mdXPld{BifXSxcHjh[5k> MlXRNVg{QTF7NEm=
H4 NYjmbG95TnWwY4Tpc44hSXO|YYm= NIPudm8xNjJizszN NVfiR4JKOjRiaB?= NVSx[JhwTE2VTx?= NIrJcHlKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ MoXiNVgxOjR3OES=
HeLa MmToSpVv[3Srb36gRZN{[Xl? NFrQdVMyODBibl2= Ml3iN|YhcA>? MUnEUXNQ M1XwNGlv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MYCxO|U3OzN6NR?=
HeLa NV7CTG5vTnWwY4Tpc44hSXO|YYm= NVXXdI9iOTByIH7N NIHLdm4{PiCq NGCzN|FFVVOR NFHUd3hKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25? NEP1R24yPzV4M{O4OS=>
HeLa MXfGeY5kfGmxbjDBd5NigQ>? NEPkNJEyODBibl2= M3LsVVM3KGh? M1G1O2ROW09? Ml\tTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NYHS[JJUOTd3NkOzPFU>
SYF MlTpSpVv[3Srb36gRZN{[Xl? MlrjNVAxKG6P MXOyOEBp M2riVWROW09? M1\4fmlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NX62bG9UOTd3NkOzPFU>
SYF Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn2UWw6OTByIH7N NUTEdYpPOjRiaB?= NGrXXlBFVVOR NUK3UoZIUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> MVixO|U3OzN6NR?=
HEK293T MYTBcpRqfmm{YXygRZN{[Xl? NG\lPHQyKG6P NVXkWGpOPCCm NXm2emV1TE2VTx?= NH3xepRKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> MVqxO|Q5PTVyMR?=
HEK293T NGXGPWNCdnSrdnnyZYwhSXO|YYm= NYXIZ2t5OSCwTR?= NFPTd|g1KGR? NVz3[|BzTE2VTx?= MlG4TY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= MUmxO|Q5PTVyMR?=
PBMC M2W0b2Z2dmO2aX;uJGF{e2G7 MWOxJI5O MVOxOEBl M2\MUGROW09? M4LocnJm\HWlZYOgR2NTPSCmZX7zbZR6 NULNR|hEOTd2OEW1NFE>
PBMC Mnj3SpVv[3Srb36gRZN{[Xl? NVHrUVBWOSCwTR?= M4rNOFE1KGR? NYXqTo4yTE2VTx?= M4TmeWRw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6 MX6xO|Q5PTVyMR?=
HEK293 cells NUHEOIlNU2mwYYPlJGF{e2G7 NX\HWY5pPTBibl2= M2X0V|Q2KG2rbh?= NFvvVHZFVVOR M3H2WWlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1? MomyNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NWXxUZpDTnWwY4Tpc44hSXO|YYm= MnnWNVAxKG6P MXi0JIg> M3LkXGROW09? NWS1bYh3UW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? MYKxO|EzQDJ4Mh?=
Human mixed lymphocyte MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHJS4J2PSCwTR?= M1\N[WROW09? MUDJR|UxRTFwNjDuUU4> MoT1NVYyQDV6NkW=
Lewis rat lymph node cells MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLVZW1xPSEQvF2= M3\kemROW09? MVnJR|UxRTJwNjFOwG0> NGHBeWcyPjF6NUi2OS=>
cells from the thymus of normal BALB/c mice MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn5N2I{OTBibl2= M1XKVFczKGh? NUPP[o1VTE2VTx?= NEXMe5ZKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7N NULBRlJtOTByMkG5OFg>
MRK-nu-1 M2LaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzxXmZOUUN3ME2wMlg1PSCyTR?= MX\TRW5ITVJ?
OCUB-M MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTVwMkSgdG0> NYrJcm1wW0GQR1XS
SF539 M33HOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPPWFJKSzVyPUGxMlYheE1? MnuxV2FPT0WU
ES4 NIfTbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vS[GlEPTB;MkGuOUBxVQ>? MYLTRW5ITVJ?
RL95-2 M2G1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP4N29nUUN3ME2xNFcheE1? Ml;UV2FPT0WU
LC-2-ad NGn4OHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWxenlQUUN3ME20NlMheE1? MmD0V2FPT0WU
Daudi MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvWcpdKSzVyPUSzOEBxVQ>? NYfD[|NxW0GQR1XS
NTERA-S-cl-D1 NHvhWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KzdmlEPTB;NESzJJBO NEGzVXVUSU6JRWK=
OS-RC-2 MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTZ3MjDwUS=> NFPmbWlUSU6JRWK=
VA-ES-BJ NGOzbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn4TWM2OD15MkOgdG0> MX;TRW5ITVJ?
GR-ST NH7qUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTh2NjDwUS=> MnLzV2FPT0WU
SW872 MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DnRmlEPTB;OES2JJBO Mnq5V2FPT0WU
NOS-1 NUDJOG9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLYZ4xkUUN3ME24O|EheE1? NGj3dlJUSU6JRWK=
MC116 M{jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLSVVZWUUN3ME25PFUheE1? Mm[1V2FPT0WU
NCI-H1355 NGjoT|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLiTWM2OD1zLkCxJI5O MlHEV2FPT0WU
RPMI-8226 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLsTWM2OD1zLkG5JI5O MX7TRW5ITVJ?
TE-15 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HLO2lEPTB;MT6zOkBvVQ>? M{TPZ3NCVkeHUh?=
Ramos-2G6-4C10 NUDCdpRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF30OY1KSzVyPUGuOFYhdk1? NFOyRoJUSU6JRWK=
KU812 M3;jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;4bWlEPTB;Mj6wNUBvVQ>? NVPqPIhMW0GQR1XS
EW-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvXTWM2OD1{LkG3JI5O NIPsTlRUSU6JRWK=
KS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCwZnNMUUN3ME2yMlQ2KG6P NEC2RWdUSU6JRWK=
SK-LMS-1 M3rxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLsTWM2OD1{LkS5JI5O MonwV2FPT0WU
TGBC1TKB MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXRWoxKSzVyPUKuOlkhdk1? NGnC[|lUSU6JRWK=
TE-6 NHflO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXiwU|cyUUN3ME2yMlc4KG6P NWjYN5UyW0GQR1XS
ETK-1 M4HjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCxTYx1UUN3ME2yMlgzKG6P NXXtXopbW0GQR1XS
BE-13 MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwOUmgcm0> M2nRdHNCVkeHUh?=
A3-KAW MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJwOUmgcm0> MlH0V2FPT0WU
TE-10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrjS4F{UUN3ME2zMlMhdk1? NX;aVJZuW0GQR1XS
DOHH-2 M3v3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPHTWM2OD1|LkO1JI5O NIDWSHlUSU6JRWK=
ES6 NVLNOHY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3VXoVKSzVyPUOuOFMhdk1? M1;aZ3NCVkeHUh?=
OPM-2 NFvDfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTvTlBkUUN3ME20MlE2KG6P M{XmPHNCVkeHUh?=
SH-4 NHfucmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfCV21KSzVyPUSuN|Qhdk1? M1H5[XNCVkeHUh?=
NB13 M2K4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz4UY1lUUN3ME20MlM3KG6P NX;jPI1xW0GQR1XS
HUTU-80 NHm1VmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXu[lJuUUN3ME20MlQzKG6P M37CbnNCVkeHUh?=
CCRF-CEM MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTRwOUSgcm0> M2X5TnNCVkeHUh?=
TGBC24TKB NHTidlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnNSYFOUUN3ME21MlUyKG6P MX\TRW5ITVJ?
697 MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwMkigcm0> MWfTRW5ITVJ?
J-RT3-T3-5 MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHVfXEzUUN3ME22MlQ3KG6P MVvTRW5ITVJ?
KALS-1 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH0WVRKSzVyPU[uOVYhdk1? M1TYU3NCVkeHUh?=
no-10 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHXT3FKSzVyPUeuNlkhdk1? MUTTRW5ITVJ?
SK-NEP-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRThwN{mgcm0> NFrrW21USU6JRWK=
L-540 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rRVGlEPTB;MUCuOFIhdk1? NX7Q[otmW0GQR1XS
JiyoyeP-2003 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzvcVhKSzVyPUGwMlk1KG6P M{SzSnNCVkeHUh?=
HH MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFzLkO5JI5O NYrHToh7W0GQR1XS
SR NF;zPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXqbmFYUUN3ME2xNU41PSCwTR?= NHn4dW1USU6JRWK=
QIMR-WIL MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\PT4FKSzVyPUGxMlg2KG6P MnHFV2FPT0WU
A4-Fuk NU[xNo81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF|LkGyJI5O NF3UbpJUSU6JRWK=
CESS NITpeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqwOo5CUUN3ME2xN{4yOyCwTR?= MVjTRW5ITVJ?
KE-37 Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD6TWM2OD1zNj6wO{BvVQ>? MWrTRW5ITVJ?
SK-UT-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPhdJBKSzVyPUG2MlgyKG6P MXTTRW5ITVJ?
SIG-M5 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfRcmw2UUN3ME2xO{4zPSCwTR?= NWLRdHRYW0GQR1XS
HT MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3RXo5bUUN3ME2xO{43KG6P MVPTRW5ITVJ?
DEL NVPoTnJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzOXIVKSzVyPUG3Mlk6KG6P MkPTV2FPT0WU
SK-PN-DW M2PFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG1TWM2OD1{MD6yN{BvVQ>? MmewV2FPT0WU
RPMI-8402 NHvWOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjMSplKSzVyPUKxMlc4KG6P NV33PXA5W0GQR1XS
RPMI-6666 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJ2LkSyJI5O NXHnUo9sW0GQR1XS
NCI-H720 NWTDbYRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX21cplTUUN3ME2yOU41OSCwTR?= NFT5VFRUSU6JRWK=
EW-16 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTjVVA3UUN3ME2yOk45PyCwTR?= NXPTXoFbW0GQR1XS
BL-70 NIfnXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ6LkO4JI5O MmLOV2FPT0WU
SF126 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTNyLkO4JI5O NWj6UZVNW0GQR1XS
BC-1 NVz2PWVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLzfnZKSzVyPUOxMlI3KG6P NVj3W254W0GQR1XS
MHH-PREB-1 NH\pOYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN{LkS0JI5O NECwfo5USU6JRWK=
A101D NInmdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln1TWM2OD1|Mj62NkBvVQ>? NE[xUGRUSU6JRWK=
NMC-G1 NGi3dFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXO0WWIyUUN3ME2zN{43PyCwTR?= MULTRW5ITVJ?
LB1047-RCC M4D1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWKydpllUUN3ME2zOE43QSCwTR?= M3PldXNCVkeHUh?=
EM-2 M3f1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLOTWM2OD1|OD61N{BvVQ>? NFvmO3lUSU6JRWK=
COLO-684 NHe4SXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTN7Lkigcm0> MWjTRW5ITVJ?
Becker MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRzLkC1JI5O M4XPSHNCVkeHUh?=
BL-41 NHf0So9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L5[mlEPTB;NEOuOlYhdk1? M4PuNXNCVkeHUh?=
MDA-MB-134-VI NH\6[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i4d2lEPTB;NESuNFIhdk1? NVfoeZJzW0GQR1XS
L-363 NHTPVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTR2LkezJI5O M3S5NHNCVkeHUh?=
ECC4 NV3qTHRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:5TWM2OD12ND63PEBvVQ>? NImwTZBUSU6JRWK=
A388 NIjDR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\1XZRKSzVyPUS0MlgzKG6P NH\xVndUSU6JRWK=
HEL NF\HdWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR7Lke5JI5O NVHoSW5EW0GQR1XS
RKO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTVyLkK5JI5O NHHTS49USU6JRWK=
KINGS-1 M3zDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\odo9KSzVyPUWxMlU2KG6P NWjldI5bW0GQR1XS
EB-3 M4fuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi2TWM2OD13Mj62O{BvVQ>? M4ni[3NCVkeHUh?=
ARH-77 NFXjdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Tn[mlEPTB;NUKuPEBvVQ>? NYX1fZVbW0GQR1XS
GCIY M2HQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjGcWlKSzVyPUWzMlQ3KG6P NYDxZ5FzW0GQR1XS
NCI-H1304 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT2eJhLUUN3ME21O{4zOiCwTR?= MYHTRW5ITVJ?
KARPAS-299 M17QUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZzLkiyJI5O NFXFeppUSU6JRWK=
IA-LM MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHHc5hOUUN3ME22PE4yOyCwTR?= M{Pz[nNCVkeHUh?=
GI-1 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M136N2lEPTB;N{CuN|khdk1? NEGy[INUSU6JRWK=
TE-11 NF\hbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXndpVGUUN3ME23O{4yPyCwTR?= M3PGdHNCVkeHUh?=
LS-411N M33kVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXOTWM2OD15Nz61O{BvVQ>? Mmj6V2FPT0WU
no-11 NYP2cYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LQVGlEPTB;OEOuNlQhdk1? NV7RdWpuW0GQR1XS
MV-4-11 NIiwOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTh|LkezJI5O NHKwOWRUSU6JRWK=
BV-173 M1jwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zU[2lEPTB;OEOuPVchdk1? M1\TPXNCVkeHUh?=
CMK NXjMPIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[0fWlEPTB;OESuNVYhdk1? MXTTRW5ITVJ?
LC4-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PjVmlEPTB;OE[uO|Ihdk1? MX;TRW5ITVJ?
COR-L279 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTh5LkK1JI5O NYLzTYx5W0GQR1XS
NCI-H209 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLOSZJIUUN3ME24O{41OSCwTR?= NV\sSI5zW0GQR1XS
Raji MkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT2TWM2OD16OT63NkBvVQ>? M4DCeHNCVkeHUh?=
LB996-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYewb4NGUUN3ME25N{41OyCwTR?= MVLTRW5ITVJ?
NCI-H526 M2e5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXFTWM2OD17Mz61PUBvVQ>? MnTvV2FPT0WU
KGN NFTwZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfqdmxoUUN3ME25Ok4zQSCwTR?= M3LLWXNCVkeHUh?=
MOLT-4 NFX1[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHtT21qUUN3ME25Ok44QSCwTR?= NVfrPHFMW0GQR1XS
PF-382 M4XFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPHSFJKSzVyPUm2Mlc6KG6P NWjkUVh[W0GQR1XS
BC-3 M4HRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnCcWR4UUN3ME25PU4yQCCwTR?= MmWxV2FPT0WU
KARPAS-422 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDpTWM2OD1zMEKuNFkhdk1? Mn7jV2FPT0WU
SBC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFyNz63OUBvVQ>? M{O5S3NCVkeHUh?=
LC-1F M1\ZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHBZXpKSzVyPUGwPE4xPSCwTR?= MnjSV2FPT0WU
GB-1 NVyxRWxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXsTWM2OD1zMEmuNFIhdk1? M1LnUXNCVkeHUh?=
SNB75 NF7HbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXYXnBKSzVyPUGxPU43QSCwTR?= NYjaSItNW0GQR1XS
BB65-RCC NV7XUGxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqwc2d7UUN3ME2xNVkvQTNibl2= NIO4R3lUSU6JRWK=
NCI-N87 M1z5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHUc2l1UUN3ME2xNlEvQThibl2= NIHY[HRUSU6JRWK=
IST-MEL1 M2f4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[2e|NKSzVyPUGyNk4{QCCwTR?= MkHUV2FPT0WU
HOP-62 M1PxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXnTWM2OD1zMk[uPFkhdk1? MlHDV2FPT0WU
ACN NED0VWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTjSoNKSzVyPUG0Ok44PSCwTR?= M1K4cHNCVkeHUh?=
DMS-114 NXmwU5NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3vNVBKSzVyPUG1NE43PyCwTR?= Mm\1V2FPT0WU
MLMA NIHaXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\xOJJ{UUN3ME2xOVkvQDhibl2= MXPTRW5ITVJ?
HT-144 NGDveoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3NTWM2OD1zNkWuOFMhdk1? M1f4SXNCVkeHUh?=
C2BBe1 M1W4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LTUmlEPTB;MU[3Mlc3KG6P M3Oxb3NCVkeHUh?=
L-428 NGDmWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTDTWM2OD1zN{euO{BvVQ>? Mn7zV2FPT0WU
DU-4475 NWLP[4pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnkSG9KSzVyPUG4O{43QCCwTR?= NX;pZYJpW0GQR1XS
CP67-MEL NYPEXHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3K1fWlEPTB;MUm5MlM5KG6P M3fKRnNCVkeHUh?=
MEG-01 M3yzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjiN|hKSzVyPUKwNU46PiCwTR?= NWDreWl2W0GQR1XS
IST-SL2 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M376U2lEPTB;MkC4MlY{KG6P M{fQcXNCVkeHUh?=
ES8 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TFS2lEPTB;MkK1Mlk1KG6P NXjn[lI1W0GQR1XS
COLO-800 M3r1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W4SGlEPTB;MkO1MlI5KG6P NHry[YJUSU6JRWK=
MFH-ino NELVO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fSV2lEPTB;MkO1Mlg1KG6P NIjxdHRUSU6JRWK=
OVCAR-4 NUTQco54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TndWlEPTB;MkO3MlI1KG6P MmXyV2FPT0WU
PSN1 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nvXmlEPTB;MkSyMlcyKG6P MVHTRW5ITVJ?
EW-12 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ2Mz6xJI5O MVfTRW5ITVJ?
HCC1599 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL1[41kUUN3ME2yOlEvPDdibl2= MUjTRW5ITVJ?
SJSA-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\pbGlEPTB;MkexMlQ3KG6P NIq1UpZUSU6JRWK=
ST486 NFPFZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrUUohKSzVyPUK5Ok4yPCCwTR?= MWnTRW5ITVJ?
NOMO-1 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTjTWM2OD1|MECuNlEhdk1? M1;BOHNCVkeHUh?=
MN-60 M4TTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNyNT6zNkBvVQ>? MV7TRW5ITVJ?
HCC1187 NWTme4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3zTWM2OD1|MEeuNlUhdk1? NHjXR45USU6JRWK=
SW982 NV;vUmcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TvOmlEPTB;M{G0Mlc2KG6P M120W3NCVkeHUh?=
LB647-SCLC Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPBXJRKSzVyPUOyPE44OSCwTR?= MkjpV2FPT0WU
HC-1 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWxWHRKSzVyPUOzOU42KG6P MojRV2FPT0WU
EHEB MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S3WGlEPTB;M{O3MlUzKG6P MlX6V2FPT0WU
TUR NFLoXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H3[2lEPTB;M{[zMlk2KG6P NVPvVVJFW0GQR1XS
LU-139 M2fJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nse2lEPTB;M{e4MlAzKG6P NV3UNI9iW0GQR1XS
NB1 NY\MT2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnofWhQUUN3ME2zPFQvPDVibl2= NGTRdGtUSU6JRWK=
BB30-HNC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fzcWlEPTB;M{i4MlMzKG6P M1LFc3NCVkeHUh?=
HAL-01 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDQTWM2OD1|OEmuNlYhdk1? M4L5VnNCVkeHUh?=
K5 M2H3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\oTWM2OD12MUGuN|chdk1? NVHjU4ZmW0GQR1XS
MZ2-MEL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3vTWM2OD12MUOuOlQhdk1? NFGzZY1USU6JRWK=
RXF393 M3T3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTmTWM2OD12MU[uOFUhdk1? M2\mcXNCVkeHUh?=
NCI-H1648 M1fHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly3TWM2OD12MUeuOVMhdk1? NV;EU2dKW0GQR1XS
TE-12 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PVWmlEPTB;NEO0MlI3KG6P MlW3V2FPT0WU
EoL-1- MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR|Nz65PEBvVQ>? M2[yfnNCVkeHUh?=
JAR NInub29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;v[2dKSzVyPUSzPE43OiCwTR?= NGTrZ3JUSU6JRWK=
DSH1 NVXmOmVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LsWWlEPTB;NEW4MlkyKG6P M2L3[HNCVkeHUh?=
NCI-H187 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzOWYJKSzVyPUS2Nk45OSCwTR?= MUPTRW5ITVJ?
HCE-4 MljSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzRTWM2OD12N{euOlYhdk1? NYe3OJQ2W0GQR1XS
8-MG-BA NVrxVHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnYbGplUUN3ME21PFEvPTJibl2= MlTOV2FPT0WU
KLE MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml76TWM2OD13OEWuNkBvVQ>? NHraWWZUSU6JRWK=
KNS-42 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LmO2lEPTB;NUi2MlgyKG6P MXLTRW5ITVJ?
MSTO-211H MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;zTWM2OD14MEmuO|Qhdk1? Mlu3V2FPT0WU
GDM-1 NHzKeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTlTWM2OD14MUSuNFkhdk1? M4LuV3NCVkeHUh?=
TE-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfabotjUUN3ME22OFYvOTJibl2= NYHi[YlOW0GQR1XS
BT-474 M4jYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTZ2Nz6wOkBvVQ>? NY\VT2s{W0GQR1XS
KARPAS-45 MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZ2Nz62JI5O NHztVmpUSU6JRWK=
MOLT-16 NIX2[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDOOFdKSzVyPU[0O{46OyCwTR?= M2PDPHNCVkeHUh?=
KURAMOCHI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fxSmlEPTB;NkW3MlUyKG6P NIPIWYhUSU6JRWK=
K-562 NWnNdWFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzTb252UUN3ME22OlkvPTFibl2= NHzBcoFUSU6JRWK=
EKVX NXfEelV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLLTWM2OD14N{KuO|Ehdk1? NUmwPGlEW0GQR1XS
GAK Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TaUWlEPTB;Nke1MlMhdk1? NGn4VWVUSU6JRWK=
NCI-SNU-5 M1HIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1y0dGlEPTB;NkmwMlAyKG6P MWjTRW5ITVJ?
NCI-H2126 NVjNdoFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TGXGlEPTB;N{K2Mlg4KG6P NUTGUYhFW0GQR1XS
CTV-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoriTWM2OD15NESuPUBvVQ>? NGDFXGlUSU6JRWK=
SW962 MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Sy[GlEPTB;N{S4MlQ1KG6P NWDIUIEyW0GQR1XS
MONO-MAC-6 M2j5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7FTWM2OD15NU[uPVMhdk1? M160WHNCVkeHUh?=
NCI-H748 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzjWotMUUN3ME23OVgvQTlibl2= Mlr4V2FPT0WU
NCI-H524 NHPUdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rMWWlEPTB;N{iwMlc{KG6P NH7HfXRUSU6JRWK=
LS-123 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DLSWlEPTB;N{m1MlY6KG6P NEC2cG5USU6JRWK=
NB7 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRThzND6xOEBvVQ>? MWjTRW5ITVJ?
LS-1034 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknNTWM2OD16MkiuPVghdk1? M1TMbHNCVkeHUh?=
TE-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS2[JNKSzVyPUi4N{42PiCwTR?= M3[wWHNCVkeHUh?=
A704 M{jHXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXoSY1TUUN3ME24PVkvOTVibl2= NUHabmhFW0GQR1XS
TK10 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33sSGlEPTB;OUG2MlA{KG6P NF7a[Y9USU6JRWK=
NCI-H345 NYXzS4o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33NZ2lEPTB;OUSzMlIzKG6P NViy[ZBMW0GQR1XS
CGTH-W-1 NFvMNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjQTHFYUUN3ME25OFgvOTNibl2= MX3TRW5ITVJ?
NCI-H510A MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[wfWNKSzVyPUm4OU4yOiCwTR?= NIjOe5VUSU6JRWK=
NCI-H1963 NHqyUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF74PWVKSzVyPUGuNFMzQTJizszN NHLx[3VUSU6JRWK=
SCC-3 NWfP[HF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O2[2lEPTB;MT6wN|QyPCEQvF2= NXW4[mtWW0GQR1XS
EW-11 NVnnXXZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LFUGlEPTB;MT6wPFc1OyEQvF2= NIf6cmdUSU6JRWK=
CPC-N MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XvPWlEPTB;MT6wPFgh|ryP MXXTRW5ITVJ?
NCI-H1417 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFwMUKyOkDPxE1? MXfTRW5ITVJ?
DG-75 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofHTWM2OD1zLkG2Nlg2KM7:TR?= NX\DfVhIW0GQR1XS
HD-MY-Z MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HZdmlEPTB;MT6xOlQyPiEQvF2= MYTTRW5ITVJ?
ATN-1 NUKxUGx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TEemlEPTB;MT6yOlIxQSEQvF2= Mn3ZV2FPT0WU
KM-H2 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi0eWZ[UUN3ME2xMlI3PDB6IN88US=> NFHmR5BUSU6JRWK=
NCI-H2081 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\pRmhKSzVyPUGuNlY3OzdizszN MVHTRW5ITVJ?
HL-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrnTWM2OD1zLkK2PVU6KM7:TR?= MkTpV2FPT0WU
DB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT0fFFKSzVyPUGuNlczPDJizszN MkjJV2FPT0WU
NCI-H1522 NXjPdFR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3QTWM2OD1zLkK4PFg4KM7:TR?= NXLh[nBVW0GQR1XS
AM-38 NFXmRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPufVRKSzVyPUGuN|A4OiEQvF2= NIXYRlRUSU6JRWK=
NCI-H446 NXjFPJFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfmZnlOUUN3ME2xMlMzOTJzIN88US=> Ml2wV2FPT0WU
SU-DHL-1 M4HWVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPjPJVKSzVyPUGuN|I5ODFizszN NHrqRXpUSU6JRWK=
NH-12 M13JVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwM{[zO|Qh|ryP M4OzfnNCVkeHUh?=
DMS-79 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwM{[4OlYh|ryP NHzYVmZUSU6JRWK=
NCI-H716 NWDhVYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoGyTWM2OD1zLkO4PVg3KM7:TR?= M{LJSXNCVkeHUh?=
ML-2 NGTIfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nWRWlEPTB;MT60NVUzQSEQvF2= NIDwXoVUSU6JRWK=
NB10 Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnVTWM2OD1zLkS2OlMzKM7:TR?= MkLCV2FPT0WU
ONS-76 M17BW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTWTWM2OD1zLkWzOVY6KM7:TR?= M{fOVnNCVkeHUh?=
LOUCY M{S3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTQTWM2OD1zLkW0OlU4KM7:TR?= NGrLTW1USU6JRWK=
SCLC-21H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTSTWM2OD1zLkW4OVgzKM7:TR?= MUfTRW5ITVJ?
TGW NXj2VXRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fsW2lEPTB;MT62N|k4PSEQvF2= M3O1VHNCVkeHUh?=
LXF-289 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwN{OyOlgh|ryP NHf5VJpUSU6JRWK=
BB49-HNC NEPtNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6wNVlKSzVyPUGuO|M2QDZizszN NXW0d5JDW0GQR1XS
NCI-H747 M2PNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwN{WzOFYh|ryP M4nNT3NCVkeHUh?=
LU-165 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFeyU4hKSzVyPUGuPFQ6QDZizszN MYDTRW5ITVJ?
OMC-1 NEnt[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwOUWwOlYh|ryP M{W1T3NCVkeHUh?=
RCC10RGB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX3TWM2OD1zLkm1PFE4KM7:TR?= M2rae3NCVkeHUh?=
SW684 M3jONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvhcpFtUUN3ME2xMlk3ODl7IN88US=> NGLiT|ZUSU6JRWK=
TE-8 NUnJbmlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETzfY9KSzVyPUKuNFU2PTlizszN NFLpV|VUSU6JRWK=
SK-N-DZ MnrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC3WoplUUN3ME2yMlE{Ojd2IN88US=> M3jpeHNCVkeHUh?=
EVSA-T NUO5[G5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fveWlEPTB;Mj6xO|MyPSEQvF2= MmjvV2FPT0WU
KASUMI-1 M1q1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwMUi4NVUh|ryP NWO3NYtWW0GQR1XS
NKM-1 NVHzZ5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe2WotpUUN3ME2yMlI2PDd{IN88US=> MmfTV2FPT0WU
CAL-148 M4PJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwM{O2NVQh|ryP NYXMXGkxW0GQR1XS
NCI-H64 M1\uVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDRToNKSzVyPUKuN|QzOzJizszN M3;iPXNCVkeHUh?=
KNS-81-FD NEDocFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ZW5d1UUN3ME2yMlM3PjJizszN NYHjPGdJW0GQR1XS
KM12 NIrTXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXiemJKUUN3ME2yMlQxQDN7IN88US=> MXnTRW5ITVJ?
SW954 NFn3XlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7uTWM2OD1{LkS3O|c6KM7:TR?= M3vrT3NCVkeHUh?=
NCI-H1395 NXfPT|BCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJwNUK2OFUh|ryP MWrTRW5ITVJ?
DJM-1 NUm1bGdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfyTWM2OD1{Lk[wOlMh|ryP MXLTRW5ITVJ?
COLO-668 M{HaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;CTWM2OD1{LkiyOlk2KM7:TR?= NFzoTWRUSU6JRWK=
NCI-H1436 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJwOEW2NVUh|ryP NXiyZ|BJW0GQR1XS
LB2241-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrlSHFVUUN3ME2yMlg3QDN7IN88US=> MXLTRW5ITVJ?
GT3TKB NYrlZ|hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\GdWlEPTB;Mj64PVA2PSEQvF2= NIiwXVlUSU6JRWK=
COLO-824 NV62RZdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm4TWM2OD1{Lki5O|Y5KM7:TR?= NVPnSmJsW0GQR1XS
ES1 M4fXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TqXGlEPTB;Mj64PVg4QSEQvF2= NXzrW3A4W0GQR1XS
LB771-HNC NVOxcFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\Wb3FKSzVyPUKuPVA6PDZizszN M3P5PHNCVkeHUh?=
GI-ME-N NGX3VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrwUIxEUUN3ME2zMlAxQTB2IN88US=> MV\TRW5ITVJ?
NALM-6 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPHTWM2OD1|LkCwPVM{KM7:TR?= NHrDblVUSU6JRWK=
LU-134-A MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17Wd2lEPTB;Mz6wOVQzPSEQvF2= M13zUXNCVkeHUh?=
DMS-153 NH\CS4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGix[mhKSzVyPUOuNFU5OjRizszN MWTTRW5ITVJ?
MZ1-PC MnHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;1OWlEPTB;Mz6wPVA4QCEQvF2= NInMbYRUSU6JRWK=
NCI-H1155 NHLXVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnyzTWM2OD1|LkGxOlEh|ryP M4\RSHNCVkeHUh?=
CAS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml6wTWM2OD1|LkGzO|A4KM7:TR?= MVLTRW5ITVJ?
D-502MG NVzvemxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWyTWM2OD1|LkG0N|kh|ryP MkfnV2FPT0WU
NCI-H2141 NYi3dGoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\KWGlEPTB;Mz6xO|Q2OiEQvF2= NU\jTJJ6W0GQR1XS
NB6 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK4b|dYUUN3ME2zMlE5OjV7IN88US=> MkC4V2FPT0WU
NCCIT NX3GN5U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTNwMkG4NFkh|ryP MknCV2FPT0WU
NB69 M{jsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz0eGxyUUN3ME2zMlMyQDlzIN88US=> MXvTRW5ITVJ?
JVM-2 M1Hkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\jSlZKSzVyPUOuN|Y1OzNizszN MYXTRW5ITVJ?
K052 M3zJb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwM{e5Olgh|ryP NV3rbXZ{W0GQR1XS
HCC2157 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXaTWM2OD1|LkWzNlI5KM7:TR?= NV;v[IxTW0GQR1XS
KMOE-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzqbGlKSzVyPUOuOVQzPDJizszN MUDTRW5ITVJ?
SF268 M4DjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LWT2lEPTB;Mz63NVU2PCEQvF2= NIDDOGVUSU6JRWK=
CHP-126 M1XuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i4dWlEPTB;Mz63OlQ2QCEQvF2= NEn4SI1USU6JRWK=
CP66-MEL M2Dxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDiTWM2OD1|Lke5NFk1KM7:TR?= NWXMeG9zW0GQR1XS
NCI-H69 M4jV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn64TWM2OD12LkCxPVM3KM7:TR?= M3jwWHNCVkeHUh?=
A253 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\jbVFKSzVyPUSuNFIyODFizszN NWf6cWNDW0GQR1XS
NB14 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPLd2ZjUUN3ME20MlExPDd7IN88US=> M1TPU3NCVkeHUh?=
NCI-H1694 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjkRXhCUUN3ME20MlE{OTF{IN88US=> NGnyVZZUSU6JRWK=
NCI-H2196 NUHWOFYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfRT4oyUUN3ME20MlE4OTZ7IN88US=> MVzTRW5ITVJ?
TE-9 NWHicm5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXmVnFIUUN3ME20MlE4PTh{IN88US=> MW\TRW5ITVJ?
D-283MED M17oZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKzNIViUUN3ME20MlE5QDRizszN NWGzN|h6W0GQR1XS
OCI-AML2 NHrLUnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nRVmlEPTB;ND6xPVQ5QSEQvF2= NETYVJdUSU6JRWK=
D-263MG NGD5WWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rnO2lEPTB;ND6yNlk3OSEQvF2= MlKwV2FPT0WU
MPP-89 M37WZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfjVJg1UUN3ME20MlI4OzB2IN88US=> MlL5V2FPT0WU
LAMA-84 M{L6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\4XINKSzVyPUSuN|A1OjFizszN NEXpc25USU6JRWK=
LB373-MEL-D NUHMZ|RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRwM{[3PFkh|ryP MnjNV2FPT0WU
UACC-257 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjhNVJ2UUN3ME20MlM6PTN2IN88US=> M3jZfXNCVkeHUh?=
MC-CAR MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRwNEO5PUDPxE1? NVi0NmdiW0GQR1XS
COLO-320-HSR NIrPXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHBdotKSzVyPUSuOFQ1OjdizszN M4K5PXNCVkeHUh?=
P30-OHK M363cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTRwNk[1PFEh|ryP NFn0TWRUSU6JRWK=
UACC-812 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrlVWM3UUN3ME20MlY6OTZzIN88US=> NIDpZotUSU6JRWK=
CTB-1 M2r3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRwN{G1OVUh|ryP NWf3[2ZMW0GQR1XS
ALL-PO MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL0TWM2OD12Lki0NFc4KM7:TR?= Mnf6V2FPT0WU
SK-MEL-2 NIHleFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLP[2pLUUN3ME20Mlg3QTV3IN88US=> NVWxcmJ[W0GQR1XS
TC-YIK M{HKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTRwOUe5OFIh|ryP NHzQWZZUSU6JRWK=
NCI-H1882 NWnwSnRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTVwMEKwNFEh|ryP MYfTRW5ITVJ?
MHH-CALL-2 M1nvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;neWlEPTB;NT6wOVA1OiEQvF2= MlP5V2FPT0WU
U-87-MG MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\t[ndOUUN3ME21MlA6PDZ4IN88US=> NF71S2JUSU6JRWK=
NCI-H1092 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHuTWM2OD13LkK2OVU2KM7:TR?= MWPTRW5ITVJ?
TE-441-T MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHFTWM2OD13LkK3PFIh|ryP NYjHR|R1W0GQR1XS
SK-MEL-1 NVu0b4w4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Tr[GlEPTB;NT6yPVA1PCEQvF2= Mn\3V2FPT0WU
EW-22 NGi4cWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe1W5htUUN3ME21MlI6PDZ4IN88US=> MUfTRW5ITVJ?
MZ7-mel MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTVwNEC2PVEh|ryP NV;aUZpsW0GQR1XS
LP-1 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTVwNEGyPVEh|ryP MYTTRW5ITVJ?
NCI-SNU-16 M1LRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLUZ|g1UUN3ME21MlY1ODd2IN88US=> NGexUotUSU6JRWK=
LU-65 M2LMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrYRo1PUUN3ME21Mlc3Ozd|IN88US=> MY\TRW5ITVJ?
CW-2 NUG1OnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KyeGlEPTB;NT64OVk2QSEQvF2= NVXU[WduW0GQR1XS
WSU-NHL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LzbWlEPTB;NT65OVE4PCEQvF2= MWDTRW5ITVJ?
IST-MES1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj2fXBKSzVyPUWuPVU1PDNizszN NYLvTIhkW0GQR1XS
U-266 NE[xNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLOVFE6UUN3ME21Mlk5OjB{IN88US=> NHvwNVlUSU6JRWK=
TALL-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3oTWM2OD14LkG0Olg5KM7:TR?= MnzLV2FPT0WU
Calu-6 M2PhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7zd2N2UUN3ME22MlE2OzF4IN88US=> Ml7JV2FPT0WU
MMAC-SF MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTZwMUi1OVYh|ryP MVjTRW5ITVJ?
NCI-H82 NVPqenE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTZwMkC0PFkh|ryP MWXTRW5ITVJ?
RS4-11 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHMTWM2OD14LkK1PFk4KM7:TR?= Mn74V2FPT0WU
SNU-C2B Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr0[JVKSzVyPU[uOFA6PjlizszN M3vNd3NCVkeHUh?=
BOKU MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v4SGlEPTB;Nj60O|U6PyEQvF2= NYH2OG5VW0GQR1XS
C8166 NFOxbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rkdmlEPTB;Nj61OVkyOiEQvF2= NHLhUI9USU6JRWK=
D-247MG MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LNbGlEPTB;Nz6wOFM1PyEQvF2= M{TPN3NCVkeHUh?=
EW-18 M164XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfIbndQUUN3ME23MlA4Ojl{IN88US=> NX\QSYp[W0GQR1XS
KG-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwNkK3N|gh|ryP NI\X[IxUSU6JRWK=
REH M1PJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnxRpBKSzVyPUeuOlgyODlizszN M{XVSXNCVkeHUh?=
U-698-M MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfZWllDUUN3ME23Mlg1OzF3IN88US=> NWKyUFBOW0GQR1XS
KP-N-RT-BM-1 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KzU2lEPTB;Nz65N|AzQSEQvF2= M4DLSnNCVkeHUh?=
MS-1 M1\QbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfLV5BKSzVyPUeuPVYxPDFizszN MkDCV2FPT0WU
SNU-C1 M2GxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSxd5BKSzVyPUeuPVgyQTJizszN NFjaZ2pUSU6JRWK=
SK-MM-2 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfQTWM2OD16LkK2NFY2KM7:TR?= M1;FUHNCVkeHUh?=
LAN-6 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPxZlhwUUN3ME24MlMxODBzIN88US=> NHz2V2pUSU6JRWK=
NEC8 NXLTb3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzYTWM2OD16LkOwOlkyKM7:TR?= MYLTRW5ITVJ?
NCI-H1770 NGjsOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG3TWM2OD16LkO4NFAzKM7:TR?= MmjQV2FPT0WU
D-336MG M12wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGzR3lOUUN3ME24MlQxOTF4IN88US=> NILRSpZUSU6JRWK=
COLO-829 Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWriOFRWUUN3ME24MlQ5QDd7IN88US=> MnLWV2FPT0WU
LS-513 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv4TWM2OD16LkW5OVk6KM7:TR?= NIHIUY5USU6JRWK=
YT NHP6NYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3N2lEPTB;OD62NlQzPyEQvF2= NVGzSFdqW0GQR1XS
EW-24 NYrXc5lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonuTWM2OD16Lke2OVQh|ryP M3G1SHNCVkeHUh?=
IST-SL1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRThwOE[1OFMh|ryP NIPNWHlUSU6JRWK=
CA46 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrx[FZKSzVyPUiuPVUxQThizszN M37qZ3NCVkeHUh?=
NCI-H1838 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWCyT2tWUUN3ME24Mlk5PjB{IN88US=> MnnjV2FPT0WU
NCI-H719 NWPvOldNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki3TWM2OD17LkK1Nlc6KM7:TR?= NHe3Wm5USU6JRWK=
HCE-T NYfRSmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn0R|RKSzVyPUmuN|A5PTFizszN MmjOV2FPT0WU
A498 NVvuVG9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLYWm1QUUN3ME25MlM3OTJ2IN88US=> MXzTRW5ITVJ?
LB831-BLC NEm3d2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvvTWM2OD17Lke2OVIyKM7:TR?= M3H4TnNCVkeHUh?=
SKM-1 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvBOIZPUUN3ME25Mlg2QTZ|IN88US=> NI\ldlJUSU6JRWK=
THP-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf1VnlqUUN3ME25Mlk3QTF6IN88US=> M4jFeHNCVkeHUh?=
SHP-77 NXXTO|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\HT2lEPTB;MUCuOFA4KM7:TR?= NV7jTFFMW0GQR1XS
EW-3 NYftVlVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DhcWlEPTB;MUCuOlI5QSEQvF2= Mn3DV2FPT0WU
KY821 MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHOeHdKSzVyPUGwMlc3OyEQvF2= NUXZd|Z2W0GQR1XS
NCI-SNU-1 NV[3XWpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFzLkCyNVch|ryP NFfKTFdUSU6JRWK=
HCC2218 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnVSmpJUUN3ME2xNU4{QTh4IN88US=> NH7ZSWZUSU6JRWK=
IM-9 NEDSW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3MOXpKSzVyPUGxMlUyODZizszN NVHQNWk3W0GQR1XS
NCI-H889 M{PVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLEPVlXUUN3ME2xNU42OzF|IN88US=> MnHYV2FPT0WU
HDLM-2 M1SwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrnR2tYUUN3ME2xNk41OTV7IN88US=> MWLTRW5ITVJ?
LB2518-MEL MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjLdJdKSzVyPUGyMlY5OTVizszN MVHTRW5ITVJ?
NCI-H23 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTzclI{UUN3ME2xN{4zPDJ3IN88US=> M{XmbXNCVkeHUh?=
NB17 NU[3b|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4OzO2lEPTB;MUOuOFU4QSEQvF2= NYHZUWh{W0GQR1XS
NCI-H322M MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLIe|I4UUN3ME2xOE41ODZ6IN88US=> NVLBNZI4W0GQR1XS
SUP-T1 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\CZW5KSzVyPUG0MlQyOyEQvF2= NF\3RopUSU6JRWK=
ES3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF3LkC3NFMh|ryP NY\4PW57W0GQR1XS
ES5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DBW2lEPTB;MUWuNFc5PyEQvF2= NEHqVZFUSU6JRWK=
NCI-H1650 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\kTWM2OD1zNT60PVc6KM7:TR?= NG\BdnVUSU6JRWK=
NCI-H226 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf2O|JKSzVyPUG1Mlg4PjhizszN M4PqfXNCVkeHUh?=
COR-L88 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmraTWM2OD1zNj6zNVQh|ryP NHPzN3pUSU6JRWK=
SCC-15 NH\aZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf0VlVKSzVyPUG2MlM5PjlizszN MXPTRW5ITVJ?
GOTO MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LGOmlEPTB;MU[uOFc6OyEQvF2= MoTTV2FPT0WU
SIMA M{L6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHrbnRKSzVyPUG2MlQ5ODJizszN NWnCT21NW0GQR1XS
NCI-H1299 NHTGTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[xTIZKSzVyPUG3MlE2QTFizszN Ml3CV2FPT0WU
NCI-H1581 M4nQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfhOnBTUUN3ME2xO{41OjF7IN88US=> NUXISpdYW0GQR1XS
MHH-NB-11 M2HLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jXZWlEPTB;MUeuPVY5OyEQvF2= NX3Sfo56W0GQR1XS
MFM-223 NEXv[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu1e40{UUN3ME2xPE4xPTN6IN88US=> MWDTRW5ITVJ?
ES7 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOzcXFvUUN3ME2xPE42PDNzIN88US=> M3vrcnNCVkeHUh?=
JVM-3 M2DrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nmdmlEPTB;MUiuO|E4KM7:TR?= M4CyZXNCVkeHUh?=
RL NHi5fYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LiNGlEPTB;MkCuN|g5KM7:TR?= M2jhT3NCVkeHUh?=
EC-GI-10 NF7UeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJzLkKwOFEh|ryP M3L1SHNCVkeHUh?=
LNCaP-Clone-FGC NWTxblBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJzLk[3Olgh|ryP NUD1TFNQW0GQR1XS
IMR-5 NX;kZY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml64TWM2OD1{MT64OFk1KM7:TR?= MXXTRW5ITVJ?
KP-N-YS M13iNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK4TZBKUUN3ME2yNU45PzVizszN M2O3OnNCVkeHUh?=
Mo-T MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLNOpFGUUN3ME2yNk4zOTh3IN88US=> MYDTRW5ITVJ?
NCI-H128 NInj[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXMTWM2OD1{Mz61PFU{KM7:TR?= NUWy[oRPW0GQR1XS
RH-1 NWfZdmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XpcGlEPTB;MkOuO|g3PiEQvF2= MmW2V2FPT0WU
NCI-H2171 NWfkWYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK4[I1KSzVyPUK0MlI1QDVizszN M3f4fXNCVkeHUh?=
RPMI-8866 NHTmXmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ4Lke0NkDPxE1? MXvTRW5ITVJ?
SK-N-FI M2DHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljZTWM2OD1{Nz6zPFEyKM7:TR?= NVHPdFFWW0GQR1XS
LOXIMVI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrZV5lKSzVyPUK3MlgxPTFizszN Mnq1V2FPT0WU
P31-FUJ NWnsVWE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jifGlEPTB;M{GuOVM4PCEQvF2= MUXTRW5ITVJ?
KMS-12-PE NV;OV5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEGzWW1KSzVyPUS5MlU{ODJizszN M3XMWXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID